AAM highlights Board Chair Bob Hoffman in new profile

WASHINGTON — The Association for Accessible Medicines (AAM) has published a detailed profile of its board chair, Bob Hoffman, highlighting his industry background and leadership priorities since his election in January.

Hoffman, chief commercial officer of U.S. Generics at Lupin Pharmaceuticals, Inc., was elected chair by AAM’s board of directors on January 29. The new profile highlights his more than thirty years of experience in the generic pharmaceutical industry and his longstanding involvement with AAM, including two terms as vice chair.

At Lupin, Hoffman played a vital role in developing and growing the company's U.S. generics division after joining in 2005. Earlier in his career, he held leadership roles at Schein Pharmaceuticals, Takeda Pharmaceutical Company, Lek Pharmaceuticals, and Pliva Pharmaceuticals, providing him with a broad perspective on the generics industry.

In remarks highlighted from ACCESS! 2026 in Miami, Hoffman emphasized what he called a return to fundamentals for the industry, highlighting disciplined execution, competition, and collaboration as key to long-term sustainability. He reiterated the importance of maintaining the Hatch-Waxman framework, which supports generic drug competition in the United States.

The AAM coverage also emphasizes Hoffman’s call for collective responsibility among member companies to improve access to affordable generic and biosimilar medicines. He highlighted ongoing pressures in the sector, including pricing issues, supply chain obstacles, and regulatory complexities, and called for increased engagement with policymakers and stakeholders.

The updated profile highlights Hoffman’s chairmanship as a key moment for the association as it continues pushing for policies that strengthen competition, improve supply chain resilience, and ensure patient access to more affordable medicines.